Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 288 of the 295 references it cites were found in a registry or an index.

Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies

Open access

Abstract

Melanoma is a highly aggressive cancer with the poorest prognosis, representing the deadliest form of skin cancer. Activating mutations in BRAF are the most frequent genetic alterations, present in approximately 50% of all melanoma cases. The use of specific inhibitors towards mutant BRAF variants and MEK, a downstream signaling target of BRAF in the MAPK pathway, has significantly improved progression-free and overall survival in advanced melanoma patients carrying BRAF mutations. Nevertheless, despite these improvements, resistance still develops within the first year of therapy in around 50% of patients, which is a significant problem in managing BRAF-mutated advanced melanoma. Understanding these mechanisms is one of the mainstreams of the research on BRAFi/MEKi acquired resistance. Both genetic and epigenetic mechanisms have been described. Moreover, in recent years, oxidative stress has emerged as another major force involved in all the phases of melanoma development, from initiation to progression until the onsets of the metastatic phenotype and chemoresistance, and has thus become a target for therapy. In the present review, we discuss the current knowledge on oxidative stress and its signaling in melanoma, as well as the oxidative stress-related mechanisms in the acquired resistance to targeted therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/antiox10121942

Cites

288 of 288 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Major ROS sources in melanocytes. ROS can be generated from UV irradiation, melanosomes, mitochondria, and NOS and NOX family enzymes. Moreover, NOX enzymes can be activated by arachidonic acid metabolites from both the COX and LOX pathways, as well as from the activated N-RAS, AKT, and RAC1 oncogenic pathways.
Figure 1 Major ROS sources in melanocytes. ROS can be generated from UV irradiation, melanosomes, mitochondria, and NOS and NOX family enzymes. Moreover, NOX enzymes can be activated by arachidonic acid metabolites from both the COX and LOX pathways, as well as from the activated N-RAS, AKT, and RAC1 oncogenic pathways.CC BY · PubMed Central
Figure 2 ROS levels and antioxidant threshold. Normal cells (N), cancer cells (C), and chemoresistant cancer cells (CC) can have different susceptibility to therapeutical approaches with drugs able to induce ROS production (drug, D). Low levels of ROS are required for cell survival, and medium levels are tolerated; however, overwhelming levels of ROS trigger cell death. N have low ROS, fully balanced by a robust antioxidant system. When ROS are increased by drug treatment, normal cells generally survive, being protected by antioxidants. Conversely, C have increased levels of basal ROS compared to normal cells. Moreover, C undergo a redox adaptation enhancing their antioxidant defenses; nevertheless, when ROS are increased by therapeutic approaches, they reach the death threshold earlier, and tumor cells can be killed more easily. In CC, ROS can be higher than in C; moreover, a consistent redox adaptation leading to an increased expression of antioxidants can be observed. In these conditions, ROS-inducing drug treatment may fail to kill cancer cells. The use of a combination of drugs that simultaneously induce new ROS generation and inhibit antioxidant defenses seems to be most promising.
Figure 2 ROS levels and antioxidant threshold. Normal cells (N), cancer cells (C), and chemoresistant cancer cells (CC) can have different susceptibility to therapeutical approaches with drugs able to induce ROS production (drug, D). Low levels of ROS are required for cell survival, and medium levels are tolerated; however, overwhelming levels of ROS trigger cell death. N have low ROS, fully balanced by a robust antioxidant system. When ROS are increased by drug treatment, normal cells generally survive, being protected by antioxidants. Conversely, C have increased levels of basal ROS compared to normal cells. Moreover, C undergo a redox adaptation enhancing their antioxidant defenses; nevertheless, when ROS are increased by therapeutic approaches, they reach the death threshold earlier, and tumor cells can be killed more easily. In CC, ROS can be higher than in C; moreover, a consistent redox adaptation leading to an increased expression of antioxidants can be observed. In these conditions, ROS-inducing drug treatment may fail to kill cancer cells. The use of a combination of drugs that simultaneously induce new ROS generation and inhibit antioxidant defenses seems to be most promising.CC BY · PubMed Central
Figure 3 Modulating oxidative stress to overcome MAPKi resistance in melanoma. Three main therapeutical strategies able to modulate oxidative stress can be considered: (i) decreasing mitochondrial activation; (ii) inhibiting antioxidant defenses; (iii) further increasing ROS production. See Section 4.1 for full explanation.
Figure 3 Modulating oxidative stress to overcome MAPKi resistance in melanoma. Three main therapeutical strategies able to modulate oxidative stress can be considered: (i) decreasing mitochondrial activation; (ii) inhibiting antioxidant defenses; (iii) further increasing ROS production. See Section 4.1 for full explanation.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

3 retracted

Research works printed but not linked: 1

  1. Gracia-Sancho, J., and Salvadó, J. (2017). Oxidative Stress and Gut Microbiota. Gastrointestinal Tissue Oxidative Stress and Dietary Antioxidant, Academic Press. Chapter 8.

Cited by

See all 79

Metadata

Authors
Pizzimenti, S., Ribero, S., Cucci, M. A., Grattarola, M., Monge, C., Dianzani, C., Barrera, G., & Muzio, G.
Affiliations
  • University of Turin (IT)
  • Department of Clinical and Biological Science, University of Turin, 10125 Turin, Italy
Corresponding author
Pizzimenti, Stefania
Venue
Antioxidants
Publisher
MDPI AG
Published
2021-12-03
Volume
10
Issue
12
Pages
1942
ISSN
2076-3921 (ISSN-L)
OpenAlex
W4200547360
Cited by
79
References
295
Citations by year
2026: 16 · 2025: 15 · 2024: 14 · 2023: 21 · 2022: 13
FWCI
1.26
Type
journal article
Language
en
Open access
Locations
  • Antioxidants (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Dipartimenti di Eccellenza (Dipartimenti di Eccellenza 2018-2022, 2018–2022, D15D18000410001)
  • Ministero dell’Istruzione, dell’Università e della Ricerca (20182022, D15D18000410001, “Dipartimenti di Eccellenza - 2018-2022”)
  • Università degli Studi di Torino (2019.2252, D15D18000410001)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
melanoma, oxidative stress, acquired drug resistance, BRAF inhibitors, MEK inhibitors, BRAF mutation, MAPK signaling, epigenetic mechanisms, chemoresistance, metastasis, antioxidant signaling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.